A State-of-the-Art Expression Platform for Expanding the Boundaries of Standard and Complex Therapeutic Protein Manufacturing
Sponsored by: ATUM-Rentschler
Over the last decades, the Pharmaceutical industry has pivoted from a chemistry-driven one to one focused on biologics. ATUM has developed Leap-In, a transposon-based platform that enables the rapid generation of exceptionally stable, high producing cell lines for biological therapeutics with excellent precision. Rentschler Biopharma has established the high performing Rentschler Expression Platform, by combining transposase mediated gene transfer with a well-proven host cell line. Based on case studies, we will demonstrate how to leverage this promising technology for a fast and efficient screening platform. The enhanced gene expression due to customized vector design, inherent stability, and optimal project timelines, through seamless integration into a well-characterized USP platform process, translates to optimal therapeutic protein production.
Privacy Policy
Sebastian has almost 10 years’ experience in the biopharmaceutical industry. This includes working as a provisional section head and permanent lab head for upstream process development, as well as process engineer for cell line development in big pharma (Sanofi) and Biotech (Ganymed Pharmaceuticals). Sebastian joined Rentschler Biopharma in 2020.
